Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – A guideline issued by the American Society of Clinical Oncology recommends that actual rather than an adjusted ideal body weight should be used…
NEW YORK (Reuters Health) – Reduced-dose chemotherapy in children with Down syndrome (DS) associated acute myeloid leukemia or myelodysplastic syndrome effectively maintains survival, researchers report in a March…
NEW YORK (Reuters Health) – In a European study, patients at high risk of recurrent gastrointestinal stromal tumor (GIST) who received imatinib (Gleevec; Novartis) for three years after…
NEW YORK (Reuters Health) – The addition of bevacizumab (Avastin; Genentech/Roche) to the standard docetaxel and prednisone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) did not…
NEW YORK (Reuters Health) – The 2009 influenza A(H1N1) pandemic caused severe illness and mortality in cancer patients with solid tumors, investigators report in Cancer online February 22.…
NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%,…
NEW YORK (Reuters Health) – When patients with advanced gastric cancer have not benefitted from one or two chemotherapy regimens for metastatic disease, salvage chemotherapy improves their overall…
NEW YORK (Reuters Health) – Two independent studies have shown that reduced-activity variants of the cytochrome P450 2D6 (CYP2D6) enzyme are not associated with poorer disease control in…
NEW YORK (Reuters Health) – The success of radiofrequency ablation (RFA) for small renal tumors is strongly dependent on tumor size, according to a study in the April…
NEW YORK (Reuters Health) – The reduced risk of developing invasive breast cancer with adjuvant tamoxifen therapy after lumpectomy and radiation for ductal carcinoma in situ (DCIS) is…
